Invitrogen™ Human CA19-9 ELISA Kit

Description

The Human CA19-9 ELISA quantitates Hu CA19-9 in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu CA19-9. Principle of the method The Human CA19-9 solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

Mucin glycoprotein is a Sialyl Lewis A structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewis A and/or Lewis B blood group antigens. In normal tissues, sialyl Lewis A antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings.